Lapaquistat
CAS: 189059-71-0
Ref. 3D-PHA05971
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Información del producto
- 1-[2-[(3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidineacetic acid
- 4-Piperidineacetic acid, 1-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
- 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)-
- 4-piperidineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-
- T 91485
Lapaquistat is a drug that inhibits the activity of protein kinase C-ε, which plays a role in regulating cholesterol synthesis. It also acts as an inhibitor of hydroxyl methyl transferase, which is involved in cholesterol synthesis. This mechanism reduces the production of low-density lipoprotein (LDL) cholesterol and other lipids. Lapaquistat has been shown to be well tolerated in clinical trials and has no significant adverse effects on blood pressure or heart rate. The chemical stability of lapaquistat was demonstrated by its ability to inhibit thp-1 cells in culture for up to 72 hours at temperatures up to 50°C.
Propiedades químicas
Consulta técnica sobre: 3D-PHA05971 Lapaquistat
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.